170 related articles for article (PubMed ID: 32246003)
1. Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity.
Nadar RA; Farbod K; der Schilden KC; Schlatt L; Crone B; Asokan N; Curci A; Brand M; Bornhaeuser M; Iafisco M; Margiotta N; Karst U; Heskamp S; Boerman OC; van den Beucken JJJP; Leeuwenburgh SCG
Sci Rep; 2020 Apr; 10(1):5889. PubMed ID: 32246003
[TBL] [Abstract][Full Text] [Related]
2. Bone tumor-targeted delivery of theranostic
Nadar RA; Franssen GM; Van Dijk NWM; Codee-van der Schilden K; de Weijert M; Oosterwijk E; Iafisco M; Margiotta N; Heskamp S; van den Beucken JJJP; Leeuwenburgh SCG
Mater Today Bio; 2021 Jan; 9():100088. PubMed ID: 33490949
[TBL] [Abstract][Full Text] [Related]
3. Dinuclear Platinum(II) Complexes with Bone-Targeting Groups as Potential Anti-Osteosarcoma Agents.
Zhang Z; Wang X; Luo C; Zhu C; Wang K; Zhang C; Guo Z
Chem Asian J; 2017 Jul; 12(13):1659-1667. PubMed ID: 28556606
[TBL] [Abstract][Full Text] [Related]
4. Platinum-bisphosphonate complexes have proven to be inactive chemotherapeutics targeted for malignant mesothelioma because of inappropriate hydrolysis.
Margiotta N; Ostuni R; Piccinonna S; Natile G; Zanellato I; Boidi CD; Bonarrigo I; Osella D
J Inorg Biochem; 2011 Apr; 105(4):548-57. PubMed ID: 21334282
[TBL] [Abstract][Full Text] [Related]
5. Coordination self-assembly of platinum-bisphosphonate polymer-metal complex nanoparticles for cisplatin delivery and effective cancer therapy.
Huang Y; He Y; Huang Z; Jiang Y; Chu W; Sun X; Huang L; Zhao C
Nanoscale; 2017 Jul; 9(28):10002-10019. PubMed ID: 28682411
[TBL] [Abstract][Full Text] [Related]
6. The drug targeting and delivery approach applied to pt-antitumour complexes. A coordination point of view.
Gabano E; Ravera M; Osella D
Curr Med Chem; 2009; 16(34):4544-80. PubMed ID: 19903151
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, characterization, and cytotoxicity of dinuclear platinum-bisphosphonate complexes to be used as prodrugs in the local treatment of bone tumours.
Margiotta N; Ostuni R; Gandin V; Marzano C; Piccinonna S; Natile G
Dalton Trans; 2009 Dec; (48):10904-13. PubMed ID: 20023921
[TBL] [Abstract][Full Text] [Related]
8. Preclinical imaging characteristics and quantification of Platinum-195m SPECT.
Aalbersberg EA; de Wit-van der Veen BJ; Zwaagstra O; Codée-van der Schilden K; Vegt E; Vogel WV
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1347-1354. PubMed ID: 28190123
[TBL] [Abstract][Full Text] [Related]
9. Controlled Release of Chemotherapeutic Platinum-Bisphosphonate Complexes from Injectable Calcium Phosphate Cements.
Farbod K; Sariibrahimoglu K; Curci A; Hayrapetyan A; Hakvoort JN; van den Beucken JJ; Iafisco M; Margiotta N; Leeuwenburgh SC
Tissue Eng Part A; 2016 May; 22(9-10):788-800. PubMed ID: 27083055
[TBL] [Abstract][Full Text] [Related]
10. Silica xerogels and hydroxyapatite nanocrystals for the local delivery of platinum-bisphosphonate complexes in the treatment of bone tumors: a mini-review.
Iafisco M; Margiotta N
J Inorg Biochem; 2012 Dec; 117():237-47. PubMed ID: 22824154
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with
Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS
J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986
[TBL] [Abstract][Full Text] [Related]
12. Dialkyl bisphosphonate platinum(II) complex as a potential drug for metastatic bone tumor.
Nakatake H; Ekimoto H; Aso M; Ogawa A; Yamaguchi A; Suemune H
Chem Pharm Bull (Tokyo); 2011; 59(6):710-3. PubMed ID: 21628905
[TBL] [Abstract][Full Text] [Related]
13. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.
Hirabayashi H; Fujisaki J
Clin Pharmacokinet; 2003; 42(15):1319-30. PubMed ID: 14674786
[TBL] [Abstract][Full Text] [Related]
14. Transferrin-functionalized nanographene oxide for delivery of platinum complexes to enhance cancer-cell selectivity and apoptosis-inducing efficacy.
Zhu H; Zhou B; Chan L; Du Y; Chen T
Int J Nanomedicine; 2017; 12():5023-5038. PubMed ID: 28761342
[TBL] [Abstract][Full Text] [Related]
15. Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery.
Huang R; Sun Y; Zhang XY; Sun BW; Wang QC; Zhu J
Biomed Pharmacother; 2015 Jul; 73():116-22. PubMed ID: 26211591
[TBL] [Abstract][Full Text] [Related]
16. Bifunctional bisphosphonate derivatives and platinum complexes with high affinity for bone hydroxyapatite.
Sun Y; Chen L; Wu X; Ding Q
Bioorg Med Chem Lett; 2017 Feb; 27(4):1070-1075. PubMed ID: 28082035
[TBL] [Abstract][Full Text] [Related]
17. Polymeric drug delivery of platinum-based anticancer agents.
Haxton KJ; Burt HM
J Pharm Sci; 2009 Jul; 98(7):2299-316. PubMed ID: 19009590
[TBL] [Abstract][Full Text] [Related]
18. Photoactivatable platinum complexes.
Bednarski PJ; Mackay FS; Sadler PJ
Anticancer Agents Med Chem; 2007 Jan; 7(1):75-93. PubMed ID: 17266506
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery to bone and mineral deposits using bisphosphonate ligands.
Cole LE; Vargo-Gogola T; Roeder RK
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):12-27. PubMed ID: 26482186
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin.
Bakalova AG; Buyukliev RT; Nikolova RP; Shivachev BL; Mihaylova RA; Konstantinov SM
Anticancer Agents Med Chem; 2019; 19(10):1243-1252. PubMed ID: 30767754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
